期刊
ALZHEIMER DISEASE & ASSOCIATED DISORDERS
卷 28, 期 3, 页码 247-252出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/WAD.0000000000000021
关键词
cognition; practice effects; amyloid imaging
资金
- anonymous foundation
- GE Healthcare
- NIH NIA [K23 AG028417]
- Molecular Imaging Program at the Huntsman Cancer Institute
- University of Utah Center for Alzheimer's Care, Imaging and Research
- NIH
- Avid Radiopharmaceuticals
- Center for Health Improvement
- Lilly
- VA Office of Rural Health
Clinical trials in Alzheimer disease are moving toward prevention studies in prodromal individuals with amyloid burden. However, methods are needed to identify individuals expected to be amyloid positive for these studies to be feasible and cost-effective. The current study sought to determine whether short-term practice effects on cognitive tests can identify those with notable uptake on amyloid imaging. Twenty-five, nondemented older adults (15 cognitively intact, 10 with mild cognitive impairment) underwent amyloid imaging through F-18-flutemetamol and 2 cognitive testing sessions across 1 week to determine practice effects on a visual memory test. Results indicated that, whereas 18F-flutemetamol uptake showed little association with baseline performance on a visual memory test (r = -0.04, P = 0.85), it was significantly correlated with practice effects across 1 week on that same memory measure (r = -0.45, P = 0.02), with greater uptake being associated with lower practice effects. The odds ratio of notable F-18-flutemetamol uptake was 5 times higher in individuals with low practice effects compared with high practice effects. Although these preliminary results need to be replicated in larger samples, short-term practice effects on cognitive tests may provide an affordable screening method to identify individuals who are amyloid positive, which could enrich samples for preventative clinical trials in Alzheimer disease.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据